脑肿瘤诊断市场 - 全球产业规模、份额、趋势、机会及预测（按诊断类型、肿瘤类型、最终用户、地区和竞争格局划分，2021-2031年）

全球脑瘤诊断市场预计将从 2025 年的 36.7 亿美元成长到 2031 年的 46.8 亿美元，复合年增长率为 4.13%。

此领域涵盖用于识别和表征颅内肿瘤的各种医疗技术，包括磁振造影(MRI)、电脑断层扫描 (CT) 和分子检测。推动该市场发展的主要因素是对及时、准确疾病检测日益增长的需求，而全球人口老化和中枢神经系统疾病发病率的上升加剧了这一需求。美国癌症协会估计，到 2025 年，美国将诊断出 24,820 例恶性脑或脊髓肿瘤病例，凸显了有效诊断能力的重要性，也印证了这一紧迫性。

儘管市场成长前景良好，但由于尖端诊断程序的高昂成本，市场仍面临许多障碍。高解析度成像和基因组分析所需的巨额费用常常限制了患者的就医和接受度，尤其是在医疗报销有限的地区。这种经济限制是主要阻碍因素，可能会阻碍这些重要诊断工具在全球更广泛的应用。

市场驱动因素

将人工智慧 (AI) 整合到诊断工作流程中是推动市场发展的关键因素，显着提高了颅内肿瘤辨识的准确性和效率。 AI 演算法正被越来越多地用于自动化 MRI 影像中复杂的肿瘤分割任务，其区分恶性组织、水肿和正常脑组织的精确度远高于人工方法。这项技术进步满足了快速制定治疗方案的迫切需求，同时最大限度地减少了放射科医生之间的差异。为了展示这项进展，Sora Neuroscience 于 2025 年 6 月宣布，其 AI 驱动的工具 Cirrus 静息态 fMRI 软体已获得 FDA核准。该软体能够快速绘製关键脑功能图，旨在改善手术决策并提高肿瘤切除术的安全性。

同时，非侵入性液态生物检体技术的兴起正在重塑市场格局，为高风险手术提供了更安全的替代方案。这些创新技术能够检测穿过血脑障壁的循环肿瘤DNA，从而无需进行侵入性颅内手术即可实现疾病进展的即时追踪和分子分析。 2025年9月，脑肿瘤研究资助联盟发布研究津贴声明，向多机构研究团队拨款100万美元，用于推动原发性脑肿瘤液态生物检体技术的发展。这项进展得到了大量投资的支持：据美国国家脑肿瘤协会称，美国国立卫生研究院预计将在2025年拨款5.18亿美元用于脑肿瘤研究，这为推进这些诊断技术的发展提供了关键的资金支持。

市场挑战

先进诊断程序的高昂成本是全球脑肿瘤诊断市场发展的主要障碍。高场磁振造影和分子生物标记分析等尖端技术需要大量资金投入，导致医疗机构和患者都面临高昂的费用。在开发中国家和健保体系薄弱的地区，这种经济负担限制了患者获得重要检测的机会，并有效地阻碍了这些诊断工具的广泛应用。因此，价格敏感地区的市场渗透率仍然很低，而医疗资源丰富的已开发国家仍产生收入。

鑑于需要对颅内肿瘤进行全面鑑别诊断的患者群体庞大，此经济障碍尤其具有限制性。高成本造成了瓶颈，抑制了此类疾病高发生率所带来的潜在需求。根据美国国家脑瘤协会估计，2024年美国将诊断出约9万例原发性脑肿瘤。这项数据凸显了庞大的临床诊断需求，但由于资金限制，这些需求仍未得到充分满足，直接阻碍了市场充分利用中枢神经系统疾病日益增长的趋势。

市场趋势

DNA甲基化谱分析的应用正在革新中枢神经系统肿瘤的分子分型，其诊断准确性远超传统组织病理学。这种表观遗传学方法透过分析DNA上的化学修饰来识别特定的肿瘤类型。它尤其适用于标准显微镜分析无法得出结论的复杂病例。透过将甲基化特征纳入诊断框架，临床医师可以更准确地对胶质瘤和生殖细胞肿瘤进行亚型分类，直接促进个人化治疗方案的发展。 2025年12月，德国癌症研究中心（DKFZ）宣布，最新版本的海德堡中枢神经系统肿瘤甲基化分类器能够区分超过180种肿瘤类型，其鑑别能力较上一版本提高了一倍，显着拓展了精准分子诊断的潜力。

同时，照护现场解决方案的出现，透过将携带式低场磁振造影（MRI）设备引入重症监护环境，提高了神经影像学的可及性。与需要屏蔽室和病患转运的传统高场核磁共振造影系统不同，这些行动装置可在加护病房）和急诊室（ER）的床边进行设置和操作，从而能够快速评估脑部病变。这一趋势缓解了可用扫描仪短缺的问题，并降低了转运严重患者的后勤风险。正如Fierce Biotech在2025年7月报导的那样，Hyperfine已开始商业化部署其获得FDA批准的下一代可携式MRI系统「Swoop」。这项研发旨在扩展即时神经影像学能力，尤其是在资源有限的临床环境中。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球脑肿瘤诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依诊断方法（影像检查、腰椎穿刺、切片检查、分子检测、其他）
  • 依肿瘤类型（转移性肿瘤、脑膜瘤、胶质母细胞瘤、脑下垂体瘤、其他）
  • 依最终使用者（医院、诊断中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美脑肿瘤诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲脑肿瘤诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区脑肿瘤诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲脑肿瘤诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲脑肿瘤诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球脑肿瘤诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• GE Healthcare Inc
• Koninklijke Philips NV
• Siemens Healthineers AG
• Fujifilm Corp
• Hitachi, Ltd.
• Hologic Inc
• NantOmics LLC
• Thermo Fisher Scientific Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Brain Cancer Diagnostics Market is projected to expand from USD 3.67 Billion in 2025 to USD 4.68 Billion by 2031, reflecting a compound annual growth rate of 4.13%. This sector encompasses a diverse array of medical technologies, such as magnetic resonance imaging, computed tomography, and molecular assays, all utilized to identify and characterize intracranial neoplasms. The primary catalyst driving this market is the escalating demand for timely and accurate disease detection, a need intensified by an aging global population and the rising frequency of central nervous system disorders. To highlight this urgency, the American Cancer Society estimated that 24,820 malignant brain or spinal cord tumors would be diagnosed in the United States in 2025, underscoring the critical necessity for effective diagnostic capabilities.

Despite these favorable growth prospects, the market confronts substantial hurdles stemming from the exorbitant costs associated with cutting-edge diagnostic procedures. The significant financial outlay required for high-resolution imaging and genomic profiling frequently restricts patient access and adoption rates, particularly in regions where healthcare reimbursement structures are limited. This economic constraint serves as a major restraint, potentially obstructing the broader global dissemination and utilization of these essential diagnostic instruments.

Market Driver

The incorporation of Artificial Intelligence into diagnostic workflows acts as a major market driver by substantially improving the accuracy and efficiency of identifying intracranial neoplasms. AI algorithms are increasingly utilized to automate complex tumor segmentation tasks within MRI scans, differentiating between malignant tissues, edema, and healthy brain matter with a level of precision that exceeds manual methods. This technological evolution satisfies the urgent requirement for rapid treatment planning while minimizing variability between radiologists. Illustrating this advancement, Sora Neuroscience announced in June 2025 the FDA clearance of its Cirrus Resting State fMRI Software, an AI-driven tool designed to quickly map essential brain functions, thereby enhancing surgical decision-making and increasing safety during tumor resections.

Simultaneously, the shift toward non-invasive liquid biopsy techniques is reshaping the market by providing safer alternatives to high-risk surgical procedures. These innovations enable the detection of circulating tumor DNA across the blood-brain barrier, allowing for real-time tracking of disease progression and molecular profiling without invasive cranial interventions. In September 2025, the Brain Tumor Funders' Collaborative released a statement regarding research grants, awarding $1 million to multi-institutional teams specifically to further liquid biopsy technologies for primary brain tumors. This progress is supported by significant investment; the National Brain Tumor Society reported that in 2025, the National Institutes of Health was projected to contribute $518 million toward brain cancer research, demonstrating the vital financial backing propelling these diagnostic capabilities forward.

Market Challenge

The elevated expense associated with advanced diagnostic procedures poses a considerable obstacle to the growth of the Global Brain Cancer Diagnostics Market. State-of-the-art modalities, including high-field magnetic resonance imaging and molecular biomarker profiling, necessitate massive capital expenditures, resulting in high costs for both healthcare providers and patients. In developing nations and regions with insufficient reimbursement systems, these financial demands curtail access to critical testing, effectively hindering the widespread implementation of these tools. As a result, market penetration in price-sensitive sectors remains low, confining significant revenue generation largely to developed economies with strong healthcare funding.

This economic barrier is especially restrictive considering the substantial number of patients needing precise differentiation of intracranial neoplasms. The high cost creates a bottleneck that stifles the potential demand generated by the prevalence of these conditions. According to the National Brain Tumor Society, an estimated 90,000 primary brain tumors were diagnosed in the United States in 2024. This statistic highlights the immense clinical necessity for diagnostics that remains partially unmet due to financial constraints, directly impeding the market's capacity to fully leverage the increasing incidence of central nervous system disorders.

Market Trends

The adoption of DNA methylation profiling is transforming the molecular classification of central nervous system tumors by providing diagnostic clarity superior to conventional histopathology. This epigenetic method examines chemical modifications on DNA to distinguish specific tumor entities, proving particularly valuable in complex cases where standard microscopic analysis yields inconclusive results. By incorporating methylation signatures into diagnostic frameworks, clinicians can attain greater precision in sub-typing gliomas and embryonal tumors, which directly informs personalized treatment plans. In December 2025, the German Cancer Research Center (DKFZ) announced that the newest iteration of its Heidelberg CNS Tumor Methylation Classifier could identify over 180 tumor types, doubling the capacity of the previous version and significantly broadening the horizon of precise molecular diagnosis.

In parallel, the emergence of point-of-care diagnostic solutions is making neuroimaging more accessible through the deployment of portable, low-field magnetic resonance imaging systems in critical care environments. Unlike traditional high-field MRI units that demand shielded rooms and patient transport, these mobile devices can be operated bedside in intensive care units and emergency rooms, allowing for the swift evaluation of brain pathology. This trend mitigates the shortage of available scanners and lowers the logistical risks involved in moving critically ill patients. As reported by Fierce Biotech in July 2025, Hyperfine began the commercial rollout of its FDA-cleared next-generation Swoop portable MRI system, a development specifically focused on extending immediate neuroimaging capabilities to resource-limited clinical settings.

Key Market Players

• GE Healthcare Inc
• Koninklijke Philips NV
• Siemens Healthineers AG
• Fujifilm Corp
• Hitachi, Ltd.
• Hologic Inc
• NantOmics LLC
• Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Brain Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Brain Cancer Diagnostics Market, By Diagnostic Type

• Imaging Test
• Lumbar Puncture
• Biopsy
• Molecular Testing
• Others

Brain Cancer Diagnostics Market, By Tumor Type

• Metastatic
• Meningioma
• Glioblastoma
• Pituitary Endoma
• Others

Brain Cancer Diagnostics Market, By End User

• Hospitals
• Diagnostics Centers
• Others

Brain Cancer Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Brain Cancer Diagnostics Market.

Available Customizations:

Global Brain Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Brain Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, Others)
  • 5.2.2. By Tumor Type (Metastatic, Meningioma, Glioblastoma, Pituitary Endoma, Others)
  • 5.2.3. By End User (Hospitals, Diagnostics Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Brain Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnostic Type
  • 6.2.2. By Tumor Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Brain Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnostic Type
      • 6.3.1.2.2. By Tumor Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Brain Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnostic Type
      • 6.3.2.2.2. By Tumor Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Brain Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnostic Type
      • 6.3.3.2.2. By Tumor Type
      • 6.3.3.2.3. By End User

7. Europe Brain Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnostic Type
  • 7.2.2. By Tumor Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Brain Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnostic Type
      • 7.3.1.2.2. By Tumor Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Brain Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnostic Type
      • 7.3.2.2.2. By Tumor Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Brain Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnostic Type
      • 7.3.3.2.2. By Tumor Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Brain Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnostic Type
      • 7.3.4.2.2. By Tumor Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Brain Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnostic Type
      • 7.3.5.2.2. By Tumor Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Brain Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnostic Type
  • 8.2.2. By Tumor Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Brain Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnostic Type
      • 8.3.1.2.2. By Tumor Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Brain Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnostic Type
      • 8.3.2.2.2. By Tumor Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Brain Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnostic Type
      • 8.3.3.2.2. By Tumor Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Brain Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnostic Type
      • 8.3.4.2.2. By Tumor Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Brain Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnostic Type
      • 8.3.5.2.2. By Tumor Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Brain Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnostic Type
  • 9.2.2. By Tumor Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Brain Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnostic Type
      • 9.3.1.2.2. By Tumor Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Brain Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnostic Type
      • 9.3.2.2.2. By Tumor Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Brain Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnostic Type
      • 9.3.3.2.2. By Tumor Type
      • 9.3.3.2.3. By End User

10. South America Brain Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnostic Type
  • 10.2.2. By Tumor Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Brain Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnostic Type
      • 10.3.1.2.2. By Tumor Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Brain Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnostic Type
      • 10.3.2.2.2. By Tumor Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Brain Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnostic Type
      • 10.3.3.2.2. By Tumor Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Brain Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GE Healthcare Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Koninklijke Philips NV
• 15.3. Siemens Healthineers AG
• 15.4. Fujifilm Corp
• 15.5. Hitachi, Ltd.
• 15.6. Hologic Inc
• 15.7. NantOmics LLC
• 15.8. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer